4llw: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==Crystal structure of Pertuzumab Clambda Fab with variable domain redesign (VRD2) at 1.95A== | |||
<StructureSection load='4llw' size='340' side='right' caption='[[4llw]], [[Resolution|resolution]] 1.95Å' scene=''> | |||
== Structural highlights == | |||
<table><tr><td colspan='2'>[[4llw]] is a 4 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4LLW OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4LLW FirstGlance]. <br> | |||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr> | |||
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4llu|4llu]], [[4lld|4lld]], [[4llm|4llm]], [[4llq|4llq]], [[4lly|4lly]]</td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4llw FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4llw OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4llw RCSB], [http://www.ebi.ac.uk/pdbsum/4llw PDBsum]</span></td></tr> | |||
</table> | |||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
Robust generation of IgG bispecific antibodies has been a long-standing challenge. Existing methods require extensive engineering of each individual antibody, discovery of common light chains, or complex and laborious biochemical processing. Here we combine computational and rational design approaches with experimental structural validation to generate antibody heavy and light chains with orthogonal Fab interfaces. Parental monoclonal antibodies incorporating these interfaces, when simultaneously co-expressed, assemble into bispecific IgG with improved heavy chain-light chain pairing. Bispecific IgGs generated with this approach exhibit pharmacokinetic and other desirable properties of native IgG, but bind target antigens monovalently. As such, these bispecific reagents may be useful in many biotechnological applications. | |||
Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface.,Lewis SM, Wu X, Pustilnik A, Sereno A, Huang F, Rick HL, Guntas G, Leaver-Fay A, Smith EM, Ho C, Hansen-Estruch C, Chamberlain AK, Truhlar SM, Conner EM, Atwell S, Kuhlman B, Demarest SJ Nat Biotechnol. 2014 Feb;32(2):191-8. doi: 10.1038/nbt.2797. Epub 2014 Jan 26. PMID:24463572<ref>PMID:24463572</ref> | |||
== | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
</div> | |||
[[Category: Atwell, S | == References == | ||
[[Category: Chamberlain, A K | <references/> | ||
[[Category: Demarest, S J | __TOC__ | ||
[[Category: Guntas, G | </StructureSection> | ||
[[Category: Hansen-Estruch, C | [[Category: Human]] | ||
[[Category: Ho, C | [[Category: Atwell, S]] | ||
[[Category: Huang, F | [[Category: Chamberlain, A K]] | ||
[[Category: Kuhlman, B | [[Category: Demarest, S J]] | ||
[[Category: Leaver-Fay, A | [[Category: Guntas, G]] | ||
[[Category: Lewis, S M | [[Category: Hansen-Estruch, C]] | ||
[[Category: Pustilnik, A | [[Category: Ho, C]] | ||
[[Category: Sereno, A | [[Category: Huang, F]] | ||
[[Category: Smith, E M | [[Category: Kuhlman, B]] | ||
[[Category: Truhlar, S M | [[Category: Leaver-Fay, A]] | ||
[[Category: Wu, X | [[Category: Lewis, S M]] | ||
[[Category: Pustilnik, A]] | |||
[[Category: Sereno, A]] | |||
[[Category: Smith, E M]] | |||
[[Category: Truhlar, S M]] | |||
[[Category: Wu, X]] | |||
[[Category: Fab]] | [[Category: Fab]] | ||
[[Category: Immune system]] | [[Category: Immune system]] | ||
